Why Contamination Control in Biopharma Can’t Rely on Old Assumptions

[Article Title]

Cell and gene therapies, multiproduct facilities, and single-use systems have made contamination risk more complex and less forgiving. Traditional cleanroom classification and visual inspection aren't enough anymore. Regulatory frameworks like Annex 1 now require a science-based contamination control strategy that proves not just that procedures exist, but that they work. Smarter cleaning and validation means less downtime, stronger audit readiness, and more reliable throughput.

Download the Document

    * denotes a required field

    Please fill out the information below. If you are already registered, and this information will be filled out for you.

  • Please enter your first and last name.

  • Please enter the name of the company or institution you work at.

  • Please enter your mailing address.

  • Please enter the e-mail address you would like to be contacted at.

  • Please enter the phone number you would like to be contacted at.

    • By submitting this form, you consent to American Pharmaceutical Review storing your email address and contact information and transmitting your contact information to the content sponsor. You may request to be removed at any time.